MERSHA M,(MD)
Urinary Tract
Infections in
Adults
1
UTI :INTRODUCTION
 Urinary tract infection is the presence of
microbial pathogens in the normally sterile
urinary tract.
 Infections are overwhelmingly bacterial although
fungi(various species of Candida),viruses(e.g. JC
virus, Adenoviruses) and parasites may cause
UTI.
2
UTI :INTRODUCTION
 The urinary tact is normally sterile and sterility
is maintained by
-- The urinary flow rate
-- Rapid bladder emptying
-- Mounting of an active inflammatory response
by WBC and
-- Antimicrobial peptides secreted by the
epithelium : defensins and cathelcidins
3
UTI:EPIDEMIOLOGY A group of diverse disorders that together constitute
the most common bacterial infection affecting humans.
 Primarily an infection of females with males affected
at the two extremes of life
 In sexually active women incidence of 0.5-0.7 per year.
60% will have at least one UTI in their lifetime.
 UTIs may involve deep tissue infection or be confined
to the bladder mucosa.
 90% of infections in males involve deep tissue invasion
and >70% of infections in women are superficial
infections. 4
UTI:EPIDEMIOLOGY(CONT’D)
 UTIs may be symptomatic or asymptomatic,
 complicated or uncomplicated.
 Upper tract( above vesicouretral junction) or lower
tract
 Asymptomatic UTI is isolation of bacteria in urine in
quantitative amounts consistent with infection but
without localizing GU 0r systemic signs or symptoms.
 Complicated UTI refers to UTI in the presence of
structural or functional abnormalities of the urinary
tract.(includes those with UTI following
instrumentation)
 Enterobacteriace the most common pathogens with
E.coli accounting for most infections.
5
UTI:PATHOGENESIS
 The ascending route the most common route of
infection(>95%).Organisms originate from the
gut flora, colonize the vagina& periurethral area
and ascend into the bladder.
 Bacterial virulence factors and host factors
determine whether infection is sustained.
 Gender is a major determinant of incidence.
 Uropathogenic E.coli have virulence properties
that mediate key steps: sustained intestinal
carriage, persistence in the vagina and ascension
and invasion of the urinary tract.
6
UTI:PATHOGENESIS(CONT’D)
 Virulence properties include the O
antigen,K
antigen,hemolysins,adhesins,etc
 Adhesins mediate attachment and
adherence via specific uroepithelial
receptors. P fimbriae the most studied
adhesins and bind to receptors in the
vagina,urinary tract, kidneys and large
intestine. The receptors are identical to
the glycosphingolipids of the P blood
group system.
7
UTI:PATHOGENESIS(CONT’D)
 Host factors in the pathogenesis include
1.Normal vaginal flora: lactobacilli in particular.
2. Normally functioning bladder: elimination by
voiding.
3.Ability to secret blood group antigens.
4.Competent ureterovesical junction.
Sexual activity is strongly correlated with UTI.
8
UTI:PATHOGENESIS(CONT’D)
 Conditions that promote occurrence of
UTI or amplify clinical impact include
1.Impedenace of urinary flow :anatomic or
functional obstruction.
2.Vesicoureteral reflux: predisposes
spread to kidney and with UTI causes
renal damage, more important in children
3. Foreign bodies e.g. Indwelling catheters
9
UTI: CLINICAL MANIFESTATIONS
 UTIs maybe asymptomatic.
 Lower tract UTI symptoms include
dysuria,frequency and suprapubic pain.
 Upper tract UTI symptoms include flank
pain,fever/chills,nausea/vomiting and CVA
tenderness.
10
UTI: DIAGNOSIS
 Culture of urine collected through
suprapubic aspiration the gold standard
for diagnosis.
 Quantitative urine culture of clean catch
urine the next best to distinguish between
true infection and contamination.
 Morning specimen preferable.
 In a young woman with typical symptoms
and pyuria the constellation of symptoms
may be diagnostic of UTI and culture may
not need to be done. 11
UTI :DIAGNOSIS(CONT’D)
 Standard definition of a positive urine culture is
> 100,000 CFU/ml.
 Acute, uncomplicated UTI in women: 100,000
CFU/ml has a specificity of 99% but sensitivity of
51%.1000 CFU /ml has a sensitivity of 80% and
specificity of 90% and is a more appropriate
criterion.
12
UTI :DIAGNOSIS(CONT’D)
 Acute urethral syndrome (symptomatic
abacteruria)in women :probably an early
variant of acute uncomplicated UTI.
>1000CFU/ml with the usual
uropathogens may suffice to make a
diagnosis,
 Acute uncomplicated pyelonephritis in
women:> 1000 CFU/ml of a single
uropathogen makes the diagnosis.
 UTI in men:>10,000CFU/ml offers a
sensitivity and specificity of >90%. 13
UTI :DIAGNOSIS(CONT’D)
 Particular infections: Infections due to
Staphylococcus saprophyticus and
Candida usually have organisms between
100 to 10,000 CFU/ml.
 In the adult with urinary symptoms
pyuria correlates closely with
UTI.Leucocyte esterase activity a good
screening test for pyuria(75-96%
sensitivity in symptomatic patients).
14
UTI :DIAGNOSIS(CONT’D)
 WBC >10/mm in unspun urine in a counting
chamber highly correlates with true
infection.Pyuria as defined by micro exam of
spun urine gives many false positives and false
negatives.
 1 or more organisms per oil immersion field with
Gram stain of unspun urine highly correlates
with significant pyuria.
15
UTI : TREATMENT
• Decisions on treatment (duration/specific
antibiotic) depend on the syndrome i.e. lower
vs upper tract UTI, susceptibility pattern of
organisms, history of drug allergy.
• Acute ,uncomplicated UTI in women:
Therapy has 3 objectives;
• 1)Eradication of lower UTI that is producing
symptoms
• 2)identifying those with silent upper
UTI(~30%)
• 3)eradication of organism from vaginal and
GI reservoirs. 16
UTI : TREATMENT(CONT’D)
 Acute, uncomplicated UTI in women: The
cornerstone of therapy is a short course(3 days) of
treatment with TMP-SMX,TMP or a
fluoroquinolone.(N.B.TMP-SMX not to be used in
areas with > 20% resistance to it by E.coli)
 If patient is asymptomatic after therapy no
further action.
 If patient is symptomatic & pyuric and bacteruric
extended treatment for 10-14 days.
 If patient symptomatic, pyuric and no bacteruria
look for Chlamydia, fungal infections, etc
17
UTI : TREATMENT(CONT’D)
• Acute pyelonephritis in women: these
patients have an invasive infection and are at
risk of bacteremia. Goals of therapy are:
• 1)control of possible urosepsis
• 2)eradication of the invading organism and
• 3) prevention of recurrences.
• Initial treatment must achieve immediate
control and should have a >99% probability of
success and : a floroquinolone, a β
lactam/aminoglycoside combination or an
advanced spectrum β lactam can be
prescribed.
• Usually treatment is IV. 18
UTI : TREATMENT(CONT’D)
 After control of sepsis oral treatment with
TMP-SMX or floroquinolone to complete a
14 day course.
 UTI in pregnancy: screening and
treatment for asymptomatic UTI justified.
Urine culture recommended at 12-16
weeks. Limited drug choice because of
toxicity, continuing follow-up is a must.
 Ampicillin, cephalosporins,
sulphonamides (except near term) can be
used. Avoid floroquinolones. 19
UTI : TREATMENT(CONT’D)
 Recurrent UTI in women : Reinfection vs
relapse.
 Relapse is recurrence with the same organism as
the pretherapy isolate whereas reinfection is
recurrence with a different organism
 Most recurrences are reinfections.First steps to
prevent reinfections include ‘
 i)Voiding after intercourse & changing
contraceptive practice
 ii) Estrogen replacement (local or systemic) in
postmenopausal women and use of cranberry or
blueberry juice.
 In those with recurrent infection after treatment
lasting <14 days it may indicate presence of a
sequestered focus(relapse) One attempt of
extended treatment i.e. 4-6 wks can be made. 20
UTI : TREATMENT(CONT’D)
• In those with recurrent reinfection in spite of
non-antimicrobial measures:
1) Low dose long term prophylaxis TMP-SMX or
floroquinolone
2)Single dose post coital treatment
3)Self- initiated short course treatment with onset
of symptoms.
Vaccines to prevent infection and probiotics to
restore the normal vaginal flora are under
investigation.
21
UTI : TREATMENT(CONT’D)
 UTI in men: should always be assumed to mean
tissue invasion of the prostate, kidney or both.
 Risk factors include lack of circumcision, anal
intercourse and acquisition from a sexual
partner.
 Standard treatment is 10-14 days of TMP-SMX
or floroquinolone.
 In those with recurrent infection after an
appropriate course of treatment urologic
evaluation as well as extended treatment(4-
6wks) required.
 Prostatic infection particularly difficult to
eradicate.
22
UTI : TREATMENT(CONT’D)
 Complicated UTI :indicates presence of
structural or functional urinary tract
defects. The range of organisms is greater
and resistance to antimicrobials is
common.
 Asymptomatic patents not to be treated
with the exception of those scheduled to
undergo UT manipulation:
 For the acutely septic, IV broad spectrum
antibiotics and oral floroquinolones for the
less ill. 23
UTI : TREATMENT(CONT’D)
 Correct the UT abnormality in conjunction with
measures to correct the abnormality.
 If abnormality is corrected 4-6 wks of “curative”
treatment to follow.
 If correction is not possible shorter courses aimed
at controlling symptoms reasonable.
24
 THANK YOU FOR YOUR ATTENTION!!!
 ANY QUESTION YOU WELL COME?
25

27 uti by mersha

  • 1.
  • 2.
    UTI :INTRODUCTION  Urinarytract infection is the presence of microbial pathogens in the normally sterile urinary tract.  Infections are overwhelmingly bacterial although fungi(various species of Candida),viruses(e.g. JC virus, Adenoviruses) and parasites may cause UTI. 2
  • 3.
    UTI :INTRODUCTION  Theurinary tact is normally sterile and sterility is maintained by -- The urinary flow rate -- Rapid bladder emptying -- Mounting of an active inflammatory response by WBC and -- Antimicrobial peptides secreted by the epithelium : defensins and cathelcidins 3
  • 4.
    UTI:EPIDEMIOLOGY A groupof diverse disorders that together constitute the most common bacterial infection affecting humans.  Primarily an infection of females with males affected at the two extremes of life  In sexually active women incidence of 0.5-0.7 per year. 60% will have at least one UTI in their lifetime.  UTIs may involve deep tissue infection or be confined to the bladder mucosa.  90% of infections in males involve deep tissue invasion and >70% of infections in women are superficial infections. 4
  • 5.
    UTI:EPIDEMIOLOGY(CONT’D)  UTIs maybe symptomatic or asymptomatic,  complicated or uncomplicated.  Upper tract( above vesicouretral junction) or lower tract  Asymptomatic UTI is isolation of bacteria in urine in quantitative amounts consistent with infection but without localizing GU 0r systemic signs or symptoms.  Complicated UTI refers to UTI in the presence of structural or functional abnormalities of the urinary tract.(includes those with UTI following instrumentation)  Enterobacteriace the most common pathogens with E.coli accounting for most infections. 5
  • 6.
    UTI:PATHOGENESIS  The ascendingroute the most common route of infection(>95%).Organisms originate from the gut flora, colonize the vagina& periurethral area and ascend into the bladder.  Bacterial virulence factors and host factors determine whether infection is sustained.  Gender is a major determinant of incidence.  Uropathogenic E.coli have virulence properties that mediate key steps: sustained intestinal carriage, persistence in the vagina and ascension and invasion of the urinary tract. 6
  • 7.
    UTI:PATHOGENESIS(CONT’D)  Virulence propertiesinclude the O antigen,K antigen,hemolysins,adhesins,etc  Adhesins mediate attachment and adherence via specific uroepithelial receptors. P fimbriae the most studied adhesins and bind to receptors in the vagina,urinary tract, kidneys and large intestine. The receptors are identical to the glycosphingolipids of the P blood group system. 7
  • 8.
    UTI:PATHOGENESIS(CONT’D)  Host factorsin the pathogenesis include 1.Normal vaginal flora: lactobacilli in particular. 2. Normally functioning bladder: elimination by voiding. 3.Ability to secret blood group antigens. 4.Competent ureterovesical junction. Sexual activity is strongly correlated with UTI. 8
  • 9.
    UTI:PATHOGENESIS(CONT’D)  Conditions thatpromote occurrence of UTI or amplify clinical impact include 1.Impedenace of urinary flow :anatomic or functional obstruction. 2.Vesicoureteral reflux: predisposes spread to kidney and with UTI causes renal damage, more important in children 3. Foreign bodies e.g. Indwelling catheters 9
  • 10.
    UTI: CLINICAL MANIFESTATIONS UTIs maybe asymptomatic.  Lower tract UTI symptoms include dysuria,frequency and suprapubic pain.  Upper tract UTI symptoms include flank pain,fever/chills,nausea/vomiting and CVA tenderness. 10
  • 11.
    UTI: DIAGNOSIS  Cultureof urine collected through suprapubic aspiration the gold standard for diagnosis.  Quantitative urine culture of clean catch urine the next best to distinguish between true infection and contamination.  Morning specimen preferable.  In a young woman with typical symptoms and pyuria the constellation of symptoms may be diagnostic of UTI and culture may not need to be done. 11
  • 12.
    UTI :DIAGNOSIS(CONT’D)  Standarddefinition of a positive urine culture is > 100,000 CFU/ml.  Acute, uncomplicated UTI in women: 100,000 CFU/ml has a specificity of 99% but sensitivity of 51%.1000 CFU /ml has a sensitivity of 80% and specificity of 90% and is a more appropriate criterion. 12
  • 13.
    UTI :DIAGNOSIS(CONT’D)  Acuteurethral syndrome (symptomatic abacteruria)in women :probably an early variant of acute uncomplicated UTI. >1000CFU/ml with the usual uropathogens may suffice to make a diagnosis,  Acute uncomplicated pyelonephritis in women:> 1000 CFU/ml of a single uropathogen makes the diagnosis.  UTI in men:>10,000CFU/ml offers a sensitivity and specificity of >90%. 13
  • 14.
    UTI :DIAGNOSIS(CONT’D)  Particularinfections: Infections due to Staphylococcus saprophyticus and Candida usually have organisms between 100 to 10,000 CFU/ml.  In the adult with urinary symptoms pyuria correlates closely with UTI.Leucocyte esterase activity a good screening test for pyuria(75-96% sensitivity in symptomatic patients). 14
  • 15.
    UTI :DIAGNOSIS(CONT’D)  WBC>10/mm in unspun urine in a counting chamber highly correlates with true infection.Pyuria as defined by micro exam of spun urine gives many false positives and false negatives.  1 or more organisms per oil immersion field with Gram stain of unspun urine highly correlates with significant pyuria. 15
  • 16.
    UTI : TREATMENT •Decisions on treatment (duration/specific antibiotic) depend on the syndrome i.e. lower vs upper tract UTI, susceptibility pattern of organisms, history of drug allergy. • Acute ,uncomplicated UTI in women: Therapy has 3 objectives; • 1)Eradication of lower UTI that is producing symptoms • 2)identifying those with silent upper UTI(~30%) • 3)eradication of organism from vaginal and GI reservoirs. 16
  • 17.
    UTI : TREATMENT(CONT’D) Acute, uncomplicated UTI in women: The cornerstone of therapy is a short course(3 days) of treatment with TMP-SMX,TMP or a fluoroquinolone.(N.B.TMP-SMX not to be used in areas with > 20% resistance to it by E.coli)  If patient is asymptomatic after therapy no further action.  If patient is symptomatic & pyuric and bacteruric extended treatment for 10-14 days.  If patient symptomatic, pyuric and no bacteruria look for Chlamydia, fungal infections, etc 17
  • 18.
    UTI : TREATMENT(CONT’D) •Acute pyelonephritis in women: these patients have an invasive infection and are at risk of bacteremia. Goals of therapy are: • 1)control of possible urosepsis • 2)eradication of the invading organism and • 3) prevention of recurrences. • Initial treatment must achieve immediate control and should have a >99% probability of success and : a floroquinolone, a β lactam/aminoglycoside combination or an advanced spectrum β lactam can be prescribed. • Usually treatment is IV. 18
  • 19.
    UTI : TREATMENT(CONT’D) After control of sepsis oral treatment with TMP-SMX or floroquinolone to complete a 14 day course.  UTI in pregnancy: screening and treatment for asymptomatic UTI justified. Urine culture recommended at 12-16 weeks. Limited drug choice because of toxicity, continuing follow-up is a must.  Ampicillin, cephalosporins, sulphonamides (except near term) can be used. Avoid floroquinolones. 19
  • 20.
    UTI : TREATMENT(CONT’D) Recurrent UTI in women : Reinfection vs relapse.  Relapse is recurrence with the same organism as the pretherapy isolate whereas reinfection is recurrence with a different organism  Most recurrences are reinfections.First steps to prevent reinfections include ‘  i)Voiding after intercourse & changing contraceptive practice  ii) Estrogen replacement (local or systemic) in postmenopausal women and use of cranberry or blueberry juice.  In those with recurrent infection after treatment lasting <14 days it may indicate presence of a sequestered focus(relapse) One attempt of extended treatment i.e. 4-6 wks can be made. 20
  • 21.
    UTI : TREATMENT(CONT’D) •In those with recurrent reinfection in spite of non-antimicrobial measures: 1) Low dose long term prophylaxis TMP-SMX or floroquinolone 2)Single dose post coital treatment 3)Self- initiated short course treatment with onset of symptoms. Vaccines to prevent infection and probiotics to restore the normal vaginal flora are under investigation. 21
  • 22.
    UTI : TREATMENT(CONT’D) UTI in men: should always be assumed to mean tissue invasion of the prostate, kidney or both.  Risk factors include lack of circumcision, anal intercourse and acquisition from a sexual partner.  Standard treatment is 10-14 days of TMP-SMX or floroquinolone.  In those with recurrent infection after an appropriate course of treatment urologic evaluation as well as extended treatment(4- 6wks) required.  Prostatic infection particularly difficult to eradicate. 22
  • 23.
    UTI : TREATMENT(CONT’D) Complicated UTI :indicates presence of structural or functional urinary tract defects. The range of organisms is greater and resistance to antimicrobials is common.  Asymptomatic patents not to be treated with the exception of those scheduled to undergo UT manipulation:  For the acutely septic, IV broad spectrum antibiotics and oral floroquinolones for the less ill. 23
  • 24.
    UTI : TREATMENT(CONT’D) Correct the UT abnormality in conjunction with measures to correct the abnormality.  If abnormality is corrected 4-6 wks of “curative” treatment to follow.  If correction is not possible shorter courses aimed at controlling symptoms reasonable. 24
  • 25.
     THANK YOUFOR YOUR ATTENTION!!!  ANY QUESTION YOU WELL COME? 25